-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-4090 in Ocular Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.T-4090 in Ocular Hypertension Drug Details: T-4090 (kinezodianone R hydrochloride) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRT-1419 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRT-1419 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRT-1419 in Refractory Acute Myeloid Leukemia Drug Details:PRT-1419 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATGTX-502 in Batten Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATGTX-502 in Batten Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATGTX-502 in Batten Disease Drug Details: ATGTX-502 is under investigation for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBP-134 in Ebolavirus Infections (Ebola Hemorrhagic Fever)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBP-134 in Ebolavirus Infections (Ebola Hemorrhagic Fever) Drug Details: MBP-134 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nazartinib Mesylate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nazartinib Mesylate in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Nazartinib Mesylate in Non-Small Cell Lung Cancer Drug Details:Nazartinib is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Wet (Neovascular / Exudative) Macular Degeneration
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OLX-301A in Wet (Neovascular / Exudative) Macular Degeneration Drug Details:OLX-301A is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimatoprost in Open-Angle Glaucoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Bimatoprost in Open-Angle Glaucoma Drug Details:Bimatoprost (T-4032) is under development for the treatment of open-angle glaucoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Decitabine in Precancerous Condition
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Decitabine in Precancerous Condition report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Decitabine in Precancerous ConditionDrug Details:Decitabine (VTD-101) is under development for the treatment of...
-
Product Insights
Keratoconjunctivitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Keratoconjunctivitis Clinical Trials Overview The Keratoconjunctivitis clinical trial report consists of 1391 trials. The report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Keratoconjunctivitis are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...